The time is now to align on a shared plan of action as a country to achieve diversity, equity, inclusion, and access in US ...

While substantial progress has been made in sharing data from clinical trials, many top-selling medicines still fall short ...

In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...

We also believe regulations over safety reporting can be burdensome and excessive ... The ICR and The Royal Marsden support moves to ensure greater transparency in clinical trials and would recommend ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

Research studies explore the different factors that affect health and lead to disease. Clinical trials test the safety and effectiveness of new cancer drugs and treatments. They help us find better ...

maintaining high standards of public transparency and safety for clinical trial participants. But the report suggests this is ...